Objective: To examine and compare the clinical efficacy of intraarticular epsilon aminocaproic acid (EACA) and tranexamic acid (TXA) in total knee arthroplasty (TKA). Methods: This study was a ...

The FDA has assigned a Prescription Drug User Fee Act target date of February 25, 2026 to the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ET-600 ...

The use of oral tranexamic acid among patients with melasma led to a 65% reduction in disease severity as well as a reduction in the levels of 5 inflammatory markers. Oral tranexamic acid (TXA) ...

The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied. In an open-label, randomized, two-period crossover study, ...

Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to ...

Hyperfibrinolysis often occurs in patients with decompensated cirrhosis and commonly results in bleeding and/or hematoma. An antifibrinolytic agent, ε-aminocaproic acid (EACA), has been used for ...

On May 28, 2025, the FDA approved Eton Pharmaceuticals' new drug application (NDA) for hydrocortisone oral solution (Khindivi) as a replacement therapy for pediatric patients aged 5 years or older ...